Becton Dickinson (BD) is a Fortune 500 global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The medical device giant’s history in Singapore stretches over 30 years, and it is one of the top three investors in Singapore’s MedTech industry. The company, which has about 1,400 staff here, has progressively invested and grown its capabilities to manage operations and strategic growth initiatives across Asia Pacific, including Australia, New Zealand and China. It started out manufacturing its devices and has since progressed to developing products and engaging in high-value research work out of Singapore.
BD’s Annex building in Tuas is its only site in Asia with a full suite of capabilities from needs identification, product and process development, to manufacturing and distribution. With its R&D close to its production capabilities, BD has been able to rapidly commercialise new products such as the Intima II™ and Pegasus™ closed catheter systems.
The company also developed the Odon Device™ in Singapore together with EDB and the World Health Organization. This obstetrical instrument is used to assist in delivery during troubled labour and is BD’s first innovation in the maternal health domain.
BD plans to further strengthen its operations in Singapore by positioning Singapore to capture future growth opportunities in Asia. The company plans to build new capabilities to provide innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, and support the management of diabetes.
In 2016, BD was awarded the Distinguished Partner in Progress (DPIP) Award by EDB for its contributions to Singapore’s economic growth. The company remains committed to its long-term partnership with the country, said BD CEO Vincent Forlenza.
“We look forward to continuing our longstanding partnership, as we see Singapore as a strategic hub in our work to advance the world of health,” he said.
